EP1959928A2 - Formulations pouvant etre pulverisees et procedes pour administrer par voie cutanee des medicaments - Google Patents

Formulations pouvant etre pulverisees et procedes pour administrer par voie cutanee des medicaments

Info

Publication number
EP1959928A2
EP1959928A2 EP06845634A EP06845634A EP1959928A2 EP 1959928 A2 EP1959928 A2 EP 1959928A2 EP 06845634 A EP06845634 A EP 06845634A EP 06845634 A EP06845634 A EP 06845634A EP 1959928 A2 EP1959928 A2 EP 1959928A2
Authority
EP
European Patent Office
Prior art keywords
formulation
drug
oil
skin surface
skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06845634A
Other languages
German (de)
English (en)
Inventor
Jie Zhang
Kevin S. Warner
Sanjay Sharma
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ZARS Pharma Inc
Original Assignee
Zars Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zars Inc filed Critical Zars Inc
Publication of EP1959928A2 publication Critical patent/EP1959928A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Definitions

  • the present invention relates generally to systems developed for dermal delivery of drugs. More particularly, the present invention relates to adhesive formulations having a viscosity suitable for sprayable application to a skin surface, and which form a sustained drug-delivery adhesive solidified layer on the skin.
  • transdermal or dermal drug delivery systems there are several kinds of transdermal or dermal drug delivery systems: skin patches, semisolids such as ointments creams and lotions, and spray-on formulations.
  • Typical drug delivery patches are not elastic and have fixed shapes and sizes. They work best on skin areas that are relatively flat and that do not flex or stretch.
  • Typical semisolid dosage forms such as ointments and creams, are often subject to unintended removal or transfer to other skin surfaces after being applied on the skin.
  • the solvent in these semisolid formulations also tends to evaporate quickly after the application, which may negatively impact drug delivery rates.
  • a semisolid formulation when a semisolid formulation is applied on skin, it is typically "rubbed in” which means only a very thin layer of the formulation is applied on the skin. This limits the amount of the drug that can be applied to each square centimeter of the skin, making sustained drug delivery difficult.
  • Spray-on formulations such as those in pressurized containers or pumps, contain ingredients of traditional semisolid formulations plus propellants and/or diluents. The propellants and diluents improve the ease of application of the formulation. Therefore, besides the method of application, they have similar limitations and shortcoming as typical semisolids, as listed above.
  • the present invention relates to novel formulations that can be applied to a skin surface by spraying, and which can form a coherent, flexible, and/or continuous solid layer after the evaporation of the propellant in the formulation.
  • film-forming technologies have been used in cosmetic and pharmaceutical preparations, typically, the solvents used in such systems do not last very long, and thus, are not optimal for sustained-release applications.
  • the use of a non-volatile solvent system, specially selected or formulated for the selected drug and for the application needs, in the formulation can improve or even optimize sustained drug delivery.
  • the non-volatile solvent(s) in the formulations can be formulated or selected stay for the duration of the application of the drug and serve as vehicle solvent for the drug.
  • a spray-on formulation for drug delivery can comprise a drug, a non-volatile solvent system comprising at least one nonvolatile solvent, a solidifying agent, and a propellant.
  • the formulation can have an initial viscosity suitable to be expelled out of a pressurized container or manual pump container and applied onto a skin surface as a layer, and further, the formulation can also be capable of forming a solidified layer on the skin surface after evaporation of at least a portion of the propellant.
  • a method for dermal drug delivery can comprise spraying onto a skin surface an adhesive, solidifying formulation.
  • the formulation can comprise a drug, a non-volatile solvent system that is flux- enabling for the drug, a solidifying agent, and a propellant.
  • the formulation can have an initial viscosity suitable to be expelled out of a pressurized container and applied onto a skin surface as a layer. Additional steps include solidifying the formulation to form a solidified layer on the skin surface by at least partial evaporation of the propellant, and dermally delivering the drug from the solidified layer to the skin surface at a therapeutically effective rate over a sustained period of time.
  • “Skin” is defined to include human skin (intact, diseased, ulcerous, or broken), finger and toe nail surfaces, and mucosal surfaces that are usually at least partially exposed to air such as lips, genital and anal mucosa, and nasal and oral mucosa.
  • drug(s) refers to any bioactive agent that is applied to, into, or through the skin which is applied for achieving a therapeutic affect. This includes compositions that are traditionally identified as drugs, as well other bioactive agents that are not always considered to be “drugs” in the classic sense, e.g., peroxides, humectants, emollients, etc., but which can provide a therapeutic effect for certain conditions.
  • drug When referring generally to a "drug,” it is understood that there are various forms of a given drug, and those various forms are expressly included.
  • various drug forms include polymorphs, salts, hydrates, solvates, and cocrystals.
  • one physical form of a drug may possess better physical-chemical properties making it more amenable for getting to, into, or through the skin, and this particular form is defined as the "physical form favorable for dermal delivery.”
  • the steady state flux of diclofenac sodium from flux enabling nonvolatile solvents is much higher than the steady state flux of diclofenac acid from the same flux enabling non-volatile solvents. It is therefore desirable to evaluate the flux of the physical forms of a drug from non-volatile solvents to select a desirable physical form/non-volatile solvent combination.
  • transdermal drug delivery or “dermal delivery of drug(s)” shall include both transdermal and topical drug delivery, and includes the delivery of drug(s) to, through, or into the skin.
  • Transdermal delivery of drug can be targeted to skin tissues just under the skin, regional tissues or organs under the skin, systemic circulation, and/or the central nervous system.
  • flux such as in the context of "dermal flux” or “transdermal flux,” respectively, refers to the quantity of the drug permeated into or across skin per unit area per unit time. A typical unit of flux is microgram per square centimeter per hour.
  • One way to measure flux is to place the formulation on a known skin area of a human volunteer and measure how much drug can permeate into or across skin within certain time constraints.
  • Various methods in vivo methods might be used for the measurements as well.
  • the method described in Example 1 or other similar method in vitro methods can also be used to measure flux.
  • flux-enabling with respect to the non-volatile solvent system (or solidified layer including the same) refers to a non-volatile solvent system (including one or more non-volatile solvents) selected or formulated specifically to be able to provide therapeutically effective flux for a particular drug(s).
  • a flux enabling non-volatile solvent system is defined as a non-volatile solvent system which, alone without the help of any other ingredients, is capable of delivering therapeutic sufficient levels of the drug across, onto or into the subject's skin when the non-volatile solvent system is saturated with the drug.
  • a flux enabling non-volatile solvent system is a non-volatile solvent system that can provide therapeutically sufficient daily doses over 24 hours when the nonvolatile solvent system is saturated with the drug and is in full contact with the subject's skin with no more than 500 cm 2 contact area.
  • the contact area for the non-volatile solvent system is no more than 100 cm 2 .
  • Testing using this saturated drug-in-solvent state can be used to measure the maximum flux- generating ability of a non-volatile solvent system.
  • the drug solvent mixture needs to be kept on the skin for a clinically sufficient amount of time. In reality, it may be difficult to keep a liquid solvent on the skin of a human volunteer for an extended period of time.
  • an alternative method to determine whether a solvent system is "flux-enabling" is to measure the in vitro drug permeation across the hairless mouse skin or human cadaver skin using the apparatus and method described in Example 1.
  • This and similar methods are commonly used by those skilled in the art to evaluate permeability and feasibility of formulations.
  • whether a non-volatile solvent system is flux-enabling can be tested on the skin of a live human subject with means to maintain the non-volatile solvent system with saturated drug on the skin, and such means may not be practical for a product.
  • the non-volatiie solvent system with saturated drug can be soaked into an absorbent fabric material which is then applied on the skin and covered with a protective membrane.
  • Such a system is not practical as a pharmaceutical product, but is appropriate for testing whether a non-volatile solvent system has the intrinsic ability to provide sufficient drug flux, or whether it is flux-enabling.
  • the solidified layer can also be "flux enabling" for the drug while some of the nonvolatile solvents remain in the solidified layer, even after the volatile solvents (including water) have been substantially evaporated.
  • therapeutically effective rate(s), refers to sufficient amounts or delivery rates of a drug which achieves any appreciable level of therapeutic results in treating a condition for which the drug is being delivered. It is understood that "appreciable level of therapeutic results” may or may not meet any government agencies' efficacy standards for approving the commercialization of a product. It is understood that various biological factors may affect the ability of a substance to perform its intended task. Therefore, an "effective amount,” “therapeutically effective amount,” or “therapeutically effective rate(s)” may be dependent in some instances on such biological factors to some degree. However, for each drug, there is usually a consensus among those skilled in the art on the range of doses or fluxes that are sufficient in most subjects.
  • “Therapeutically effective flux” or “therapeutically sufficient flux” is defined as the permeation flux of the selected drug that delivers sufficient amount of drug into or across the skin to be clinically beneficial. "Clinically beneficial” or “clinically sufficient” when referring to flux means at some of the patient population can obtain some degree of benefit from the drug flux. It does not necessarily mean that most of the patient population can obtain some degree of benefit or the benefit is high enough to be deemed “effective” by relevant government agencies or the medical profession.
  • therapeutically effective flux refers to the drug flux that can deliver a sufficient amount of the drug into the target tissues within a clinically reasonable amount of time.
  • therapeutically effective flux refers to drug flux that, via clinically reasonable skin contact area, can deliver sufficient amounts of the selected drug to generate clinically beneficial plasma or blood drug concentrations within a clinically reasonable time.
  • Clinically reasonable skin contact area is defined as a size of skin application area that most subjects would accept. Typically, a skin contact area of 400 cm 2 or less is considered reasonable.
  • the flux needs to be at least 4000 mcg/400cm 2 /10 hour, which equals 1 mcg/cm 2 /hr.
  • different drugs have different "therapeutically effective flux.”
  • Therapeutically sufficient flux may be different in different subjects and or at different times for even the same subject. However, for each drug, there is usually a consensus among the skilled in the art on the range of doses or fluxes that are sufficient in most subjects at most times.
  • the therapeutically effective flux values in Table A represent the steady state flux values of marketed products through hairless mouse or human epidermal membrane in an in vitro system described in Example 1. These values are meant only to be estimates and to provide a basis of comparison for formulation development and optimization.
  • the therapeutically effective flux for a selected drug could be very different for different diseases to be treated for, different stages of diseases, and different individual subjects. It should be noted that the flux listed may be more than therapeutically effective.
  • plasticizing in relation to flux-enabling non-volatile solvent(s) is defined as a flux-enabling non-volatile solvent that acts as a plasticizer for the solidifying agent.
  • a "plasticizer” is an agent which is capable of increasing the percentage elongation of the formulation after the volatile solvent system has at least substantially evaporated. Plasticizers also have the capability to reduce the brittleness of solidified formulation by making it more flexible and/or elastic.
  • propylene glycol is a "flux-enabling, plasticizing non-volatile solvent" for the drug ketoprofen with polyvinyl alcohol as the selected solidifying agent.
  • propylene glycol in a formulation of ketoprofen with Gantrez S- 97 or Avalure UR 405 as solidifying agents does not provide the same plasticizing effect.
  • the combination of propylene glycol and Gantrez S-97 or Avalure UR 405 is less compatible and results in less desirable formulation for topical applications. Therefore, whether a given non-volatile solvent is "plasticizing" depends on which solidifying agent(s) is selected. Different drugs often have different matching flux-enabling non-volatile solvent systems which provide particularly good results. Examples of such are noted in Table C. Experiments were carried out as described in Example 1 below and the results are further discussed in the subsequent Examples 2-9.
  • flux-enabling non-volatile solvent can be a single chemical substance or a mixture of two or more chemical substances.
  • the steady state flux value for clobetasol propionate in Table C is a 9:1 for propylene glycol:isostearic acid mixture that generated much higher clobetasol flux than propylene glycol or ISA alone (see Table B). Therefore, the 9:1 propylene glycohisostearic acid mixture is a "high flux- enabling non-volatile solvent” but propylene glycol or isostearic acid alone is not.
  • adheresion and "adhesive” when referring to a solidified layer herein refer to sufficient adhesion between the solidified layer and the skin so that the layer does not fall off the skin during intended use on most subjects.
  • Adhesive or the like when used to describe the solidified layer can also mean the solidified layer is adhesive to the skin surface to which the initial formulation layer was originally applied (before the evaporation of the volatile solvent(s)). In one embodiment, it does not mean the solidified layer is adhesive on the opposing side.
  • whether a solidified layer can adhere to a skin surface for the desired extended period of time partially depends on the condition of the skin surface.
  • the adhesive solidified layer of the current invention may not be able to maintain perfect contact with the skin surface and deliver the drug over a sustained period of time for every subject under any conditions on the skin surface.
  • a standard is that it maintains good contact with most of the skin surface, e.g. 70% of the total area, over the specified period of time for most subjects under normal conditions of the skin . surface and external environment.
  • a solidified layer that exhibits acceptably flexibility, elasticity, and adhesion to skin can be attached to human skin over a flexible skin location, e.g., elbow, finger, wrist, neck, lower back, lips, knee, etc., and will remain substantially intact on the skin upon stretching of the skin. It should be noted that the solidified layers of the present invention do not necessarily have to have any elasticity in some embodiments.
  • peelable when used to describe the solidified layer, means the solidified layer can be lifted from the skin surface in one large piece or several large pieces, as opposed to many small pieces or crumbs.
  • the term "sustained” relates to therapeutically effective rates of dermal drug delivery for a continuous period of time of at least 30 minutes, and in some embodiments, periods of time of at least about 2 hours, 4 hours, 8 hours, 12 hours, 24 hours, or longer.
  • the use of the term “substantially” when referring to the evaporation of the volatile solvents means that a majority of the volatile solvents which were included in the initial formulation have evaporated.
  • a solidified layer is said to be “substantially devoid” of volatile solvents, including water, the solidified layer has less than 10 wt%, and preferably less than 5 wt%, of the volatile solvents in the solidified layer as a whole.
  • propellant refers to a solvent which has a boiling point less than 20 0 C and which can generate adequate pressure in a closed container at temperatures above 20 0 C to expel the formulations of the present invention from the container.
  • the propellant can be in dissolved in rest of the formulation, exist as a separate phase (separated or suspended) in the rest of the formulation, or exist in a separate enclosure (bag in can types) or compartment.
  • the propellant can be mixed with the other components of the formulation prior to application to a skin surface, such as by shaking, inverting, agitation, or other manual or mechanical mixing methods.
  • Volatile solvent system refers to a single solvent or combination of solvents that are volatile, including water and solvents that are more volatile than water, but which have a boiling point which is greater than 25 0 C.
  • Non-volatile solvent system can be a single solvent or mixture of solvents that are less volatile than water. It can also contain substances that are solid or liquid at room temperatures, such as pH or ion-pairing agents. After evaporation of the volatile solvent system, most of the non-volatile solvent system should remain in the solidified layer for an amount of time sufficient to dermally delivery a given drug to, into, or through the skin of a subject at a sufficient flux for a period of time to provide a therapeutic effect. In some embodiments, in order to obtain desired permeability for an active drug and/or compatibility with solidifying agents or other ingredients of the formulation, a mixture of two or more non-volatile solvents can be used to form the non-volatile solvent system.
  • the combination of two or more nonvolatile solvents to form a solvent system provides a higher transdermal flux for a drug than the flux provided for the drug by each of the non-volatile solvents individually.
  • the non-volatile solvent system may also serve as a plasticizer of the solidified layer, so that the solidified layer is elastic and flexible.
  • Adhesive solidifying formulation or “solidifying formulation,” “sprayable solidifying formulation”, and the like, are used interchangeably and refer to a composition that has a viscosity suitable for application to a skin surface prior to evaporation of its volatile solvent(s), and which can become a solidified layer after evaporation of at least a portion of the volatile solvent(s).
  • the solidified layer once formed, can be very durable.
  • the formulation once solidified on a skin surface, the formulation can form a peel.
  • the peel can be a soft, coherent solid that can be removed by peeling large pieces from the skin relative to the size of the applied formulation, and often, can be peeled from the skin as a single piece.
  • the application viscosity is typically more viscous than a water-like liquid, but less viscous than a soft solid.
  • preferred viscosities include materials that have consistencies similar to pastes, gels, ointments, and the like, e.g., viscous liquids that flow but are not subject to spilling.
  • a composition is said to have a viscosity "suitable for application" to a skin surface, this means the composition has a viscosity that is high enough so that the composition does not substantially run off the skin after being applied to skin, but also has a low enough viscosity so that it can be easily spread onto the skin.
  • a viscosity range that meets this definition can be from about 100 cP to about 3,000,000 cP (centipoises), and more preferably from about 1,000 cP to about 1,000,000 cP.
  • the additional adhesive agent or substance can be an additional non-volatile solvent or an additional solidifying agent.
  • Non-limiting examples of substances which might be used as additional adhesion enhancing agents include copolymers of methylvinyl ether and maleic anhydride (Gantrez polymers), polyethylene glycol and polyvinyl pyrrolidone, gelatin, low molecular weight polyisobutylene rubber, copolymer of acrylsan alkyl/octylacrylamido (Dermacryl 79), and various aliphatic resins and aromatic resins.
  • the terms "washable” or “removed by washing” when used with respect to the adhesive formulations of the present invention refers to the ability of the adhesive formulation to be removed by the application of a washing solvent using a normal or medium amount of washing force.
  • washing solvents which can be used for removing by washing the formulations of the present invention are numerous, but preferably are chosen from commonly acceptable solvents including the volatile solvents listed herein. Preferred washing solvents do not significantly irritate human skin and are generally available to the average subject. Examples of washing solvents include but are not limited to water, ethanol, methanol, isopropyl alcohol, acetone, ethyl acetate, propanol, or combinations thereof.
  • the washing solvents can be selected from the group consisting of water, ethanol, isopropyl alcohol or combinations thereof.
  • Surfactants can also be used in some embodiments.
  • drying time or “acceptable length of time” refer to the time it takes for the formulation to form a non-messy solidified surface after application on skin under standard skin and ambient conditions, and with standard testing procedure. It is noted that the word “drying time” in this application does not mean the time it takes to completely evaporate off the volatile solvent(s). Instead, it means the time it takes to form the non-messy solidified surface as described above.
  • Standard skin is defined as dry, healthy human skin with a surface temperature of between about 30 0 C to about 36 0 C.
  • Standard ambient conditions are defined by the temperature range of from 2O 0 C to 25°C and a relative humidity range of from 20% to 80%.
  • the term "standard skin” in no way limits the types of skin or skin conditions on which the formulations of the present invention can be used.
  • the formulations of the present invention can be used to treat all types of "skin,” including undamaged (standard skin), diseased skin, or damaged skin.
  • skin conditions having different characteristics can be treated using the formulations of the present invention, the use of the term "standard skin” is used merely as a standard to test the compositions of the varying embodiments of the present invention.
  • formulations that perform well e.g., solidify, provide therapeutically effective flux, etc.
  • Standard testing procedure or “standard testing condition” is as follows: To standard skin at standard ambient conditions is applied an approximately 0.1 mm layer of the adhesive solidifying formulation and the drying time is measured. The drying time is defined as the time it takes for the formulation to form a non-messy surface such that the formulation does not lose mass by adhesion to a piece of 100% cotton cloth pressed onto the formulation surface with a pressure of between about 5 and about 10 g/cm 2 for 5 seconds.
  • Solidified layer describes the solidified layer of an adhesive solidifying formulation after at least a portion of the volatile solvent system has evaporated. The solidified layer remains adhered to the skin, and is preferably capable of maintaining good contact with the subject's skin for substantially the entire duration of application under standard skin and ambient conditions.
  • the solidified layer also preferably exhibits sufficient tensile strength so that it can be peeled off the skin at the end of the application in one piece or several large pieces (as opposed to a layer with weak tensile strength that breaks into many small pieces or crumbles when removed from the skin).
  • a plurality of drugs, compounds, and/or solvents may be presented in a common list for convenience. However, these lists should be construed as though each member of the list is individually identified as a separate and unique member. Thus, no individual member of such list should be construed as a de facto equivalent of any other member of the same list solely based on their presentation in a common group without indications to the contrary.
  • a spray-on formulation for drug delivery can comprise a drug, a non-volatile solvent system comprising at least one nonvolatile solvent, a solidifying agent, and a propellant.
  • the formulation can have an initial viscosity suitable to be expelled out of a pressurized container or manual pump container and applied onto a skin surface as a layer, and further, the formulation can also be capable of forming a solidified layer on the skin surface after evaporation of at least a portion of the propellant.
  • a method for dermal drug delivery can comprise spraying onto a skin surface an adhesive, solidifying formulation.
  • the formulation can comprise a drug, a non-volatile solvent system that is flux- enabling for the drug, a solidifying agent, and a propellant.
  • the formulation can have an initial viscosity suitable to be expelled out of a pressurized container and applied onto a skin surface as a layer. Additional steps include solidifying the formulation to form a solidified layer on the skin surface by at least partial evaporation of the propellant, and dermally delivering the drug from the solidified layer to the skin surface at a therapeutically effective rate over a sustained period of time.
  • these embodiments exemplify the present invention which is related to novel formulations, methods, and solidified layers.
  • the formulations are sprayable onto skin surfaces, form solidified layers that can quickly (from 15 seconds to about 4 minutes under standard skin and ambient conditions) to moderately quickly (from about 4 to about 15 minutes under standard skin and ambient conditions) change into a solidified layer, e.g., a coherent and soft solid layer that is optionally peelable, for drug delivery.
  • the solidified layer thus formed is capable of delivering drug to the skin, into the skin, or across the skin, etc., at a therapeutically effective rate over a sustained period of time, e.g., 30 minutes to tens of hours, so that most of the active drug that is delivered to the subject is delivered after the solidified layer is formed.
  • the solidified layer formed by the formulations of the present invention typically adheres to the skin, but has a solidified, minimally-adhering, outer surface which is formed relatively soon after application and which does not substantially transfer to or otherwise soil clothing or other objects that a subject is wearing or that the solidified layer may inadvertently contact.
  • the solidified layer can also be formulated such that it is highly flexible and stretchable, and thus capable of maintaining good contact with a skin surface, even if the skin is stretched during body movement, such as at a knee, finger, elbow, other joints, lips, etc.
  • the user sprays the formulation on the skin surface.
  • the formulation forms a thin, wet layer on the skin surface.
  • the propellant (and the optional volatile solvent(s)) evaporates, the formulation solidifies into a thin, non-rigid, coherent, flexible, continuous, and/or preferably elastic solid layer.
  • This solid layer has sufficient adhesion to the skin surface so that it can maintain good contact with the skin surface for the desired length of time, typically hours to tens of hours. Since the non-volatile solvent system does not evaporate and is designed to provide sufficient flux across the skin surface for the drug, the drug can be delivered from the solidified layer into or across the skin surface continuously for a sustained period of time or substantially for the entire duration of the application period.
  • the propellant can be selected from pharmaceutically or cosmetically acceptable solvents known in the art to be useful for pressurized spray-on applications.
  • propellants which can be used include hydrofluorocarbons, hydrochlorofluorocarbon, ethers or alkanes.
  • the propellant can be in dissolved in the formulation, exist as a separate phase or as a suspended phase in the rest of the formulation, exist in a separate enclosure (bag in can types), or exist in a separate compartment and be mixed with the rest of the formulation to provide the propulsion at the application time.
  • the weight percentage of the propellant can be from about 4 wt% to about 90 wt%, and more preferably from about 10 wt% to about 60 wt%.
  • Some embodiments of the present invention can also comprise a volatile solvent.
  • volatile solvents which can be used include, but are not limited to, iso-amyl acetate, denatured alcohol, methanol, propanol, chlorobutanol, turpentine, cytopentasiloxane, cyclomethicone, methyl ethyl ketone, etha ⁇ ol, isopropyl alcohol, water, ethyl acetate, acetone, or combinations thereof.
  • these volatile solvents should be chosen to be compatible with the rest of the formulation. When used, it is desirable that an appropriate weight percentage of the volatile solvent(s) be present in the formulation. Too much of the volatile solvent system prolongs the drying time.
  • the non-volatile solvent system can also be chosen or formulated to be compatible with the solidifying agent, the drug, the propellant, and any other ingredients that may be present.
  • the solidifying agent can be chosen so that it is dispersible or soluble in the non-volatile solvent system.
  • Most non-volatile solvent systems as a whole will be formulated appropriately after experimentation. For instance, certain drugs have good solubility in poly ethylene glycol (PEG) having a molecular weight of 400 (PEG 400, non-volatile solvent) but poor solubility in glycerol (non-volatile solvent) and water (volatile solvent).
  • PEG 400 cannot effectively dissolve poly vinyl alcohol (PVA), and thus, is not very compatible alone with PVA, a solidifying agent.
  • PVA poly vinyl alcohol
  • a non-solvent system including PEG 400 and glycerol (compatible with PVA) in an appropriate ratio can be formulated, achieving a compatibility compromise.
  • compatibility non-volatile solvent/solidifying agent incompatibility is observed when Span 20 is formulated into a solidifying formulation containing PVA. With this combination, Span 20 can separate out of the formulation and form an oily layer on the surface of the solidified layer.
  • non-volatile solvent(s) that can be used alone or in combination to form non-volatile solvent systems can be selected from a variety of pharmaceutically acceptable liquids.
  • the non-volatile solvent system can include glycerol, propylene glycol, isostearic acid, oleic acid, propylene glycol, trolamine, tromethamine, triacetin, sorbitan monolaurate, sorbitan monooleate, sorbitan monopalmitate, butanol, or combinations thereof.
  • the non-volatile solvent system can include benzoic acid, butyl alcohol, dibutyl sebecate, diglycerides, dipropylene glycol, eugenol, fatty acids such as coconut oil, fish oil, palm oil, grape seed oil, isopropyl myristate, mineral oil, oleyl alcohol, vitamin E, triglycerides, sorbitan fatty acid surfactants, triethyl citrate, or combinations thereof.
  • benzoic acid butyl alcohol, dibutyl sebecate, diglycerides, dipropylene glycol, eugenol, fatty acids such as coconut oil, fish oil, palm oil, grape seed oil, isopropyl myristate, mineral oil, oleyl alcohol, vitamin E, triglycerides, sorbitan fatty acid surfactants, triethyl citrate, or combinations thereof.
  • the non-volatile solvent system can include 1 ,2,6-hexanetriol, alkyltriols, alkyldiols, acetyl monoglycerides, tocopherol, alkyl dioxolanes, p- propenylanisole, anise oil, apricot oil, dimethyl isosorbide, alkyl glucoside, benzyl alcohol, bees wax, benzyl benzoate, butylene glycol, caprylic/capric triglyceride, caramel, cassia oil, castor oil, cinnamaldehyde, cinnamon oil, clove oil, coconut oil, cocoa butter, cocoglycerides, coriander oil, corn oil, coriander oil, corn syrup, cottonseed oil, cresol, cyclomethicone, diacetin, diacetylated monoglycerides, diethanolamine, dietthylene glycol monoethyl ether, diglycerides
  • non-volatile solvent system can also serve as plasticizer in the adhesive formulation so that when the solidified layer is formed, the layer is flexible, stretchable, and/or otherwise "skin friendly.”
  • Certain ingredients in the formulations may be irritating to the skin may be desirable to use to achieve the desired solubility and/or permeability of the drug. In those cases, it is desirable to add compounds that are both capable of preventing or reducing skin irritation and are compatible with the formulation.
  • a non-volatile solvent that is capable of reducing skin irritation. Examples of solvents that are known to be capable of preventing or reducing skin irritation include, but are not limited to, glycerin, honey, and/or propylene glycol.
  • the formulations of the present invention may also contain two or more non-volatile solvents that independently are not flux-enabling non-volatile solvents for a drug, but when formulated together become flux enabling nonvolatile solvents as part of a system.
  • One possible reason that these initially non-flux-enabling non-volatile solvents become flux-enabling non-volatile solvents when formulated together may be due to the optimization of the ionization state of the drug to a physical form which has higher flux, or alternatively, the non-volatile solvents together act in some other synergistic manner.
  • One further benefit of the mixing of the non-volatile solvents is that it may optimize the pH of the formulation or the skin tissues under the formulation layer to minimize irritation.
  • non-volatile solvents examples include, but are not limited to, isostearic acid /trolamine, isostearic acid/diisopropyl amine, oleic acid/trolamine, propylene glycol /isostearic acid.
  • the selection of the solidifying agent(s) can also be carried out in consideration of the other components present in the adhesive formulation.
  • the solidifying agent can be selected or formulated to be compatible to the drug and the propellants and the non-volatile solvent system (and optionally, other volatile solvents that are not propellants), as well as to provide desired physical properties to the solidified layer once it is formed.
  • the solidifying agent can be selected from a variety of agents.
  • the solidifying agent can include polyvinyl alcohol with a MVV range of 20,000-70,000 (Amresco), esters of polyvinylmethylether/maleic anhydride copolymer (ISP Gantrez ES- 425 and Gantrez ES-225) with a MW range of 80,000-160,000, neutral copolymer of butyl methacrylate and methyl methacrylate (Degussa Plastoid B) with a MW range of 120,000-180,000, dimethylaminoethyl methacrylate-butyl methacrylate-methyl methacrylate copolymer (Degussa Eudragit E100) with a MW range of 100,000-200,000, ethyl acrylate-methyl methacrylate- trimethylammonioethyl methacrylate chloride copolymer with a MW greater than 5,000 or similar MW to Eudragit RLPO (Degussa), Zein (prolamine) with a MW greater
  • the solidifying agent can include ethyl cellulose, hydroxy ethyl cellulose, hydroxy methyl cellulose, hydroxy propyl cellulose, hydroxypropyl methyl cellulose, carboxymethyl cellulose, methyl cellulose, polyether amides, corn starch, pregelatinized corn starch, polyether amides, shellac, polyvinyl pyrrolidone, polyisobutylene rubber, polyvinyl acetate phthalate or combinations thereof.
  • the solidifying agent can include ammonia methacrylate, carrageenan, cellulose acetate phthalate aqueous such as CAPNF from Eastman, carboxy polymethylene, cellulose acetate (microcrystalline), cellulose polymers, divinyl benzene styrene, ethylene vinyl acetate, silicone, guar gum, guar rosin, gluten, casein, calcium caseinate, ammonium caseinate, sodium caseinate, potassium caseinate, methyl acrylate, microcrystalline wax, polyvinyl acetate, PVP ethyl cellulose, acrylate, PEG/PVP, xantham gum, trimethyl siloxysilicate, maleic acid/anhydride colymers, polacrilin, poloxamer, polyethylene oxide, poly glactic acid/poly-I-lactic acid, turpene resin, locust bean gum, acrylic copolymers, polyurethane dispersions, dextrin, polyvinyl alcohol-pol
  • the solidifying agent can include a combination of solidifying agents set forth in the any of the above discussed embodiments.
  • Other polymers may also be suitable as the solidifying agent, depending on the solvent(s), the drug, and the specific functional requirements of the given formulation.
  • Other polymers may also be suitable as the solidifying agent, depending on the solvent(s), the drug, and the specific functional requirements of the given formulation.
  • the non-volatile solvent system and the solidifying agent(s) should be compatible with each other.
  • Compatibility can be defined as i) the solidifying agent does not substantially negatively influence the function of the non-volatile solvent system, except for some reduction of flux; ii) the solidifying agent can hold the non-volatile solvent system in the solidified layer so that substantially no non-volatile solvent oozes out of the layer, and/or iii) the solidified layer formed with the selected non-volatile solvent system and the solidifying agent has acceptable flexibility, rigidity, tensile strength, elasticity, and adhesiveness to skin.
  • the weight ratio of the non-volatile solvent system to the solidifying agent(s) can be from about 0.1:1 to about 10:1. In another aspect, the weight ratio of the non-volatile solvent system to the solidifying agent can be from about 0.2:1 to about 4:1 , and more preferably from about 0.5:1 to about 2:1.
  • a solidified layer which is optionally also a peel
  • certain nonsteroidal anti-inflammatory agents can be sprayed directly over joints and muscles to form a solidified layer for transdermal delivery into joints and muscles.
  • NSAIDs nonsteroidal anti-inflammatory agents
  • skin areas over joints and certain muscle groups are often significantly stretched during body movements. Such movement prevents non- stretchable patches from maintaining good skin contact.
  • Lotions, ointments, creams, gels, foams, pastes, or the like also may not be suitable for use for the reasons cited above.
  • the sprayable solidifying formulations of the present invention can offer unique advantages and benefits. It should be pointed out that although good stretchability can be desirable in some applications, the sprayable solidifying formulations of the present invention do not always need to be stretchable, as certain applications of the present invention do not necessarily benefit from this property.
  • a further feature of a formulation prepared in accordance with embodiments of the present invention is related to drying time. If the formulation dries too slowly, the subject may have to wait a long time before resuming normal activities (e.g. putting clothing on) that may remove un- solidifled formulation. Thus, it is desirable for the drying time to be shorter than about 15 minutes, preferably shorter than 3 minutes, and most preferably shorter than 1 minute.
  • the solidified layers of the present invention include the presence of a physical barrier that can be formed by the solidified layer itself.
  • the skin surface is sensitive to the touch of foreign objects or vulnerable to infection if contact by foreign objects.
  • the solidified layer can provides physical protection to the skin surface.
  • local anesthetic agents and other agents such as clonidine may be delivered topically for treating pain related to neuropathy, such as diabetic neuropathic pain. Since many of such subjects feel tremendous pain, even when their skin area is only gently touched, the physical barrier of the solidified layer can prevent or minimize pain caused by accidental contact with objects or others.
  • sprayable formulations of the present invention can be applied to a skin surface without the need to touch or rub the skin surface.
  • sprayable application of the solidifying formulation allows for the application of medicated formulation without the need to touch or rub the skin.
  • a spray-on solidified formulation of a corticosteroid for treating alopecia can be applied easier than a traditional semi-solid formulation onto a scalp area that has some hair.
  • spray application can be beneficial is in damaged or infected skin.
  • Subjects having damaged or infected skin or tissue may not be able to withstand the pain associated with non-spray-on formulations. Additionally, when a formulation requires the subject to physically touch the damaged or infected skin, the risk of a new or increased infection is also increased.
  • the spray-on formulations can provide other important advantages over currently available "spray formulations" or "semi-solid” formulations.
  • the solidified layers of the present invention formed from the spray-on solidifying formulations can hold a higher amount of drug for more sustained delivery.
  • the sprayable solidified formulations of the present invention can be easier to apply or can be applied without touching the skin surface with an application device such as a spatula.
  • the skin surfaces to which the formulations of the current invention can be applied include but are not limited to skin, mucosal surfaces of the lip, genitals, and anus, nail surface, wound surface, bed sore surface, and diabetes-induced ulcerous skin surface.
  • the present invention provides a convenient means of applying a solidifying formulation in combination with liquefied propellants to readily form a uniform solidified layer which will remain in intimate contact with the site of application, and provide active drug delivery. This requires applying sufficient quantities of the formulation per unit area of the skin surface so that the solidified layer can contain sufficient amount of the drug. For most drugs the solidified layer needs to be at least 0.01 mm thick, and preferably at least 0.05 mm thick.
  • the formulation can be readily sprayed onto a skin surface without the need to touch the surface which could cause pain or infection of the area.
  • the solidified layer comprises a non-volatile solvent system that is flux-enabling for the drug so that the drug can be delivered over sustained period of time at therapeutically effective rates. Further, as the solidified layer remains adhesive to skin and is preferably peelable, easy removal of the solidified layer can occur, and may occur without the aid of a solvent or surfactant.
  • the adhesion to skin and elasticity of the material is such that the solidified layer will not separate from the skin upon skin stretching at highly stretchable skin areas, such as over joints and muscles.
  • the solidified layer can be stretched by 5%, or even 10% or greater, in at least one direction without cracking, breaking, and/or separating form a skin surface to which the layer is applied.
  • the solidified layer can be formulated to advantageously deliver drug and protect sensitive skin areas.
  • the solidified layer may be washed off with a solvent, such as water or ethanol, at the end of the desired drug delivery.
  • a solvent such as water or ethanol
  • Other solvents which could also be used to wash off the solidified formulation include but are not limited to the volatile solvents listed herein.
  • the ability to be removed by washing is particularly advantageous for certain applications. For example, if the solidifying formulation is applied to a skin surface with a lot of hair (e.g. an anti genital herpes solidifying formulation applied on genital skin area with pubic hair), removal by peeling might cause discomfort and therefore be undesirable, and hence washing can be a preferred form of removal in this type of application.
  • the ability for removal by peeling may be secondary consideration to a formulation that will adhere to the skin surface.
  • a solidified layer formulated to be easily washed off by water or ethanol can be more desirable.
  • the solvent used to wash off the solidified layer may dissolve the layer or make it less adhesive to the skin so that it can be easily removed from the skin.
  • a solidifying formulation has a viscosity such that it may be dispensed from a container (aerosol or pump-spray) with a metered dose or volumetric control such that a controlled amount of the solidifying formulation is dispensed.
  • the formulation comprises the components as described in the embodiments described above. Controlling the amount of formulation dispensed can avoid under-dosing or overdosing that may lead to undesirable therapeutic effect and/or adverse side effects.
  • a system having two components includes a solidifying formulation with viscosity such that it may be dispensed from a pressurized container, and a pressurized container.
  • the formulation comprises a solidifying agent, at least one non-volatile solvent, a drug, a propellant, and optionally a volatile solvent system.
  • the aerosol container containing the formulation and the propellant can be shaken to mix the propellant and the rest of the formulation into a temporary suspension which has the appropriate viscosity to be sprayed on a skin surface.
  • the formulation forms a drug-delivering solidified layer on the skin that can be easily removed after use.
  • the pressurized container can include a mechanism which causes the propellant to mix with the rest of the formulation to form a mixture that is expelled from the container onto a skin surface.
  • the formulation forms a drug-delivering solidified layer on the skin that can be easily removed after use.
  • a solidifying formulation has a viscosity such that it may be dispensed from a manual pump-spray container or a conventional pump spray container.
  • the formulation includes a solidifying agent, a nonvolatile solvent system, a drug, and optionally a volatile solvent(s).
  • the drug formulation has the appropriate viscosity such that it can easily be expelled from the manual pump-spray container and applied to the skin surface. Once applied the formulation will form a drug-delivering solidified layer on the skin surface that can be easily removed after use.
  • the solidified layers of the present invention can keep a substantial amount of the non-volatile solvent system, which is optimized for delivering the drug, on the skin surface.
  • This feature can provide unique advantages over existing products. For example, in some semi-solid formulations, upon application to a skin surface, the volatile solvents quickly evaporate and the formulation layer solidifies into a hard lacquer-like layer. The drug molecules are immobilized in the hard lacquer layer and are substantially unavailable for delivery into the skin surface. As a result, it is believed that the delivery of the drug is not sustained over a long period of time.
  • a solidified layer can include bupivacaine, lidocaine, tetracaine, and/or ropivacaine, and can be formulated for treating diabetic and post herpetic neuralgia.
  • dibucanine and an alpha-2 agonist such as clonidine can be formulated in a solidifying formulation for treating the same disease.
  • retinoic acid and benzoyl peroxide can be combined in a solidified layer for treating acne, or alternatively, 1 wt% clindamycin and 5 wt% benzoyl peroxide can alternatively be combined in a solidifying formulation for treating acne.
  • a retinol solidifying formulation can be prepared for treating wrinkles, or a lidocaine solidifying formulation can be prepared for treating back pain.
  • a zinc oxide solidifying formulation (OTC) can be prepared for treating diaper rash (the physical barrier provided by the solidified layer against irritating urine and feces is believed to be beneficial), or an antihistamine solidified layer can be prepared for treating allergic rashes such as that caused by poison ivy.
  • Additional applications include delivering drugs for treating certain skin conditions, e.g., dermatitis, psoriasis, eczema, skin cancer, alopecia, wrinkles, viral infections such as cold sore, genital herpes, shingles, etc., particularly those that occur over joints or muscles where a transdermal patch may not be practical.
  • drugs for treating certain skin conditions e.g., dermatitis, psoriasis, eczema
  • skin cancer e.g., dermatitis, psoriasis, eczema
  • wrinkles e.g., wrinkles, viral infections such as cold sore, genital herpes, shingles, etc.
  • viral infections such as cold sore, genital herpes, shingles, etc.
  • solidifying formulations containing imiquimod can be formulated for treating skin cancer, prematurely aged skin, photo-damaged skin, common and genital warts, and actinic kera
  • Solidifying formulations containing antiviral drugs such as acyclovir, penciclovir, famciclovir, valacyclovir, steroids, and/or behenyl alcohol can be formulated for treating herpes viral infections such as cold sores on the face and genital areas.
  • Solidifying formulations containing non-steroidal anti-inflammatory drugs (NSAIDs), capsaicin, alpha-2 agonists, and/or nerve growth factors can be formulated for treating soft tissue injury and musde-skeletal pains such as joint and back pain of various causes. As discussed above, patches over these skin areas typically do not have good contact over sustained period of time, especially for a physically active subject, and may cause discomfort.
  • NSAIDs non-steroidal anti-inflammatory drugs
  • capsaicin capsaicin
  • alpha-2 agonists alpha-2 agonists
  • nerve growth factors can be formulated for treating soft tissue injury and musde-skeletal pains such as joint and back pain of various causes.
  • patches over these skin areas typically do
  • solidifying formulations of the present invention address the shortcomings of both of these types of delivery systems.
  • One embodiment can entail a solidified layer containing a drug from the class of alpha-2 antagonists which is applied topically to treat neuropathic pain.
  • the alpha-2 agonist is gradually released from the formulation to provide pain relief over a sustained period of time.
  • the formulation can become a coherent, soft solid within about 5 minutes and remains adhered to the skin surface for the length of its application, typically hours to tens of hours.
  • the solidified layer is easily removed after the intended application without leaving residual formulation on the skin surface.
  • Another embodiment involves a solidifying formulation containing capsaicin which is applied topically to treat neuropathic pain.
  • the capsaicin is gradually released from the formulation for treating this pain over a sustained period of time.
  • the formulation can become a coherent, soft solid within about 5 minutes and remains adhered to the skin surface for the length of its application. It can be easily removed any time after drying without leaving residual formulation on the skin surface.
  • Another embodiment involves a solidifying formulation containing clobetasol propionate which is applied topically to treat hand dermatitis.
  • the clobetasol propionate is gradually released from the formulation for treating dermatitis over a sustained period of time.
  • the formulation can become a coherent, soft solid within about 3 minutes and remains adhered to the skin surface for the length of its application.
  • the physical barrier also protects the compromised skin from potentially harmful substances. It is easily removed any time after drying without leaving residual formulation on the skin surface.
  • Another embodiment involves a solidifying formulation containing clobetasol propionate which is applied topically to treat alopecia.
  • the clobetasol propionate is gradually released from the formulation for promoting hair growth over a sustained period of time.
  • the formulation can become a coherent, soft solid within about 5 minutes and remains adhered to the skin surface for the length of its application. It is easily removed any time after drying by peeling to showering.
  • Another embodiment involves sprayable solidifying formulations containing tazorac for treating stretch marks, wrinkles, sebaceous hyperplasia, or seborrheic keratosis.
  • solidifying formulations containing glycerol can be made so as to provide a protective barrier for fissu ring on fingertips.
  • Still another embodiment can include a solidifying formulation containing a drug selected from the local anesthetic class, including lidocaine and ropivacaine, or the like, or NSAID class, such as ketoprofen, piroxicam, diclofenac, indomethacin, or the like.
  • a drug selected from the local anesthetic class including lidocaine and ropivacaine, or the like, or NSAID class, such as ketoprofen, piroxicam, diclofenac, indomethacin, or the like.
  • NSAID class such as ketoprofen, piroxicam, diclofenac, indomethacin, or the like.
  • the local anesthetic and/or NSAID is/are gradually released from the formulation to provide pain relief over a sustained period of time.
  • the formulation can become a coherent, soft solid within about 3 minutes and remain adhered to the skin surface for the length of its application. It is easily removed any time after drying without leaving residual formulation on
  • a further embodiment involves a solidifying formulation containing at least one alpha-2 agonist drug, at least one tricyclic antidepressant agent, and/or at least one local anesthetic drug which is applied topically to treat neuropathic pain.
  • the drug(s) are gradually released from the formulation to provide pain relief over a sustained period of time.
  • the formulation can become a coherent, soft solid within about 3 minutes and remains adhered to the skin surface for the length of its application. It can be easily removed any time after drying without leaving residual formulation on the skin surface.
  • a similar embodiment can include a solidifying formulation containing drugs capsaicin and a local anesthetic drug which is applied topically to the skin to provide pain relief.
  • Another embodiment can include a solidifying formulation containing the combination of a local anesthetic and a NSAID.
  • the drugs are gradually released from the formulation to provide pain relief over a sustained period of time.
  • the formulation can become a coherent, soft solid within about 3 minutes and remains adhered to the skin surface for the length of its application. It is easily removed any time after drying without leaving residual formulation on the skin surface.
  • solidifying formulations for the delivery of drugs useful for treating the causes or symptoms of diseases involving joints and muscles can also benefit from the systems, formulations, and methods of the present invention.
  • diseases that may be applicable include, but not limited to, osteoarthritis (OA), rheumatoid arthritis (RA), joint and skeletal pain of various other causes, myofascial pain, muscular pain, and sports injuries.
  • Drugs or drug classes that can be used for such applications include, but are not limited to, non-steroidal anti-inflammatory drugs (NSAlDs) such as ketoprofen and diclofanac, COX-2 selective NSAIDs and agents, COX-3 selective NSAIDs and agents, local anesthetics such as lidocaine, bupivacaine, ropivacaine, and tetracaine, and steroids such as dexamethasone.
  • NSAlDs non-steroidal anti-inflammatory drugs
  • ketoprofen and diclofanac COX-2 selective NSAIDs and agents
  • COX-3 selective NSAIDs and agents COX-3 selective NSAIDs and agents
  • local anesthetics such as lidocaine, bupivacaine, ropivacaine, and tetracaine
  • steroids such as dexamethasone.
  • Delivering drugs for the treatment of acne and other skin conditions can also benefit from principles of the present invention, especially when delivering drugs having low skin permeability.
  • topical retinoids, peroxides, and antibiotics for treating acne are mostly applied as traditional semisolid gels or creams.
  • sustained delivery over many hours is unlikely.
  • clindamycin, benzoyl peroxide, and erythromycin may be efficacious only if sufficient quantities are delivered into hair follicles.
  • a traditional semisolid formulation such as the popular acne medicine benzaclin gel, typically loses most of its solvent (water in the case of benzaclin) within a few minutes after the application.
  • the formulations of the present invention typically do not have this limitation.
  • the delivery of drugs for treating neuropathic pain can also benefit from the methods, systems, and formulations of the present invention.
  • a patch containing a local anesthetic agent, such as LidodermTM is widely used for treating neuropathic pain, such as pain caused by post-herpetic neuralgia. Due to the limitations of the patch as discussed above, the solidified layers prepared in accordance with the present invention provide some unique benefits, as well as provide a potentially less expensive alternative to the use of a patch.
  • Possible drugs delivered for such applications include, but are not limited to, local anesthetics such as lidocaine, prilocaine, tetracaine, bupivicaine, etidocaine; and/or other drugs including capsaicin and alpha-2 agonists such as clonidine, dissociative anesthetics such as ketamine, and/or tricyclic antidepressants such as amitriptyline,.
  • local anesthetics such as lidocaine, prilocaine, tetracaine, bupivicaine, etidocaine
  • other drugs including capsaicin and alpha-2 agonists such as clonidine, dissociative anesthetics such as ketamine, and/or tricyclic antidepressants such as amitriptyline,.
  • the solidifying formulations of the present invention can be formulated to treat a variety of conditions and disease such as musculoskeletal pain, neuropathic pain, alopecia, skin disease including dermatitis and psoriasis as well as skin restoration (cosmetic skin treatment), and infections including viral, bacterial, and fungal infection.
  • the formulations can deliver a wide ranging number and types of drugs and active agents.
  • the solidifying formulation can be formulated to include acyclovir, econazole, miconazole, terbinafine, lidocaine, bupivacaine, ropivacaine, and tetracaine, amitriptyline, ketanserin, betamethasone dipropionate, triamcinolone acetonide, clindamycin, benzoyl peroxide, tretinoin, Isotretinoin, clobetasol propionate, halobetasol propionate, ketoprofen, piroxicam, diclofenac, indomethacin, imiquimod, salicylic acid, benzoic acid, or combinations thereof
  • the formulation can include an antifungal drug such as amorolfine, butenafine, naftifine, terbinafine, fluconazole, itraconazole, ketoconazole, posaconazole, ravuconazole, voricon
  • the formulation can include an antifungal drug such as acyclovir, penciclovir, famciclovir, valacyclovir, behenyl alcohol, trifluridine, idoxuridine, cidofovir, gancyclovir, podofilox, podophyllotoxin.ribavirin, abacavir, delavirdine, didanosine, efavirenz, lamivudine, nevirapine, stavudine, zalcitabine, zidovudine, amprenavir, indinavir, nelfinavir, ritonavir, saquinavir, amantadine, interferon, oseltamivir, ribavirin, rimantadine, zanamivir, or combinations thereof.
  • an antifungal drug such as acyclovir, penciclovir, famciclovir, valacyclovir, behenyl alcohol
  • the formulation When the formulation is intended to provide antibacterial treatment, it can be formulated to include an antibacterial drug such as erythromycin, clindamycin, tetracycline, bacitracin, neomycin, mupirocin, polymyxin B, quinolones such as ciproflaxin, or combinations thereof.
  • an antibacterial drug such as erythromycin, clindamycin, tetracycline, bacitracin, neomycin, mupirocin, polymyxin B, quinolones such as ciproflaxin, or combinations thereof.
  • the formulation when the formulation is intended to relieve pain, particularly neuropathic pain, can include a local anesthetic such as lidocaine, bupivacaine, ropivacaine, and/or tetracaine; and/or an alpha-2 agonists such as clonidine.
  • a local anesthetic such as lidocaine, bupivacaine, ropivacaine, and/or tetracaine
  • an alpha-2 agonists such as clonidine.
  • the formulation when the formulation is intended to treat pain associated with inflammation, it can be formulated to include an non-steroidal anti-inflammatory drug such as ketoprofen, piroxicam, diclofenac, indomethacin, COX inhibitors general COX inhibitors, COX-2 selective inhibitors, COX-3 selective inhibitors, or combinations thereof.
  • the formulation can be formulated to treat skin disorders or blemishes by including active agents such as anti-acne drugs such as clindamycin and benzoyl peroxide, retinol, vitamin A derivatives such as tazarotene and isotretinoin, cyclosporin, anthralin, vitamin D3, cholecalciferol, calcitriol, cafcipotriol, tacalcitol, calcipotriene, etc.
  • active agents such as anti-acne drugs such as clindamycin and benzoyl peroxide, retinol, vitamin A derivatives such as tazarotene and isotretinoin, cyclosporin, anthralin, vitamin D3, cholecalciferol, calcitriol, cafcipotriol, tacalcitol, calcipotriene, etc.
  • active agents such as anti-acne drugs such as clindamycin and benzoyl
  • anti-wart compounds include but are not limited to:imiquimod, rosiquimod, keratolytic agents: salicylic acid, alpha hydroxy acids, sulfur, rescorcinol, urea, benzoyl peroxide, allantoin, tretinoin, trichloroacetic acid, lactic acid, benzoic acid, or combinations thereof.
  • a further embodiment involves the use of the solidifying formulations for the delivery of sex steroids including, but not limited to, progestagens consisting of progesterone, norethindrone, norethindroneacetate, desogestrel, drospirenone, ethynodiol diacetate, norelgestromin, norgestimate, levonorgestrel, dl-norgestrel, cyproterone acetate, dydrogesterone, medroxyprogesterone acetate, chlormadinone acetate, megestrol, promegestone, norethisterone, lynestrenol, gestodene, tibolene, androgens consisting of testosterone, methyl testosterone, oxandrolone, androstenedione, dihydrotestosterone, estrogens consisting of estradiol, ethniyl estradiol, estiol, estrone, conjug
  • Non-sex steroids can also be delivered using the formulations of the present invention.
  • examples of such steroids include, but are not limited to, betamethasone dipropionate, halobetasol propionate, diflorasone diacetate, triamcinolone acetonide, desoximethasone, fluocinonide, halcinonide, mometasone furoate, betamethasone valerate, fluocinonide, fluticasone propionate, triamcinolone acetonide, fluocinolone acetonide, flurandrenolide, desonide, hydrocortisone butyrate, hydrocortisone valerate, alclometasone dipropionate, flumethasone pivolate, hydrocortisone, hydrocortisone acetate, or combinations thereof.
  • a further embodiment involves controlled delivery of nicotine for treating nicotine dependence among smokers and persons addicted to nicotine.
  • Formulations of the present invention would be a cost effective way of delivering therapeutic amounts of nicotine transdermally.
  • Another embodiment involves using the formulation to deliver antihistamine agents such as diphenhydramine and/or tripelennamine. These agents would reduce itching by blocking the histamine that causes the itch and also provide relief by providing topical analgesia.
  • antihistamine agents such as diphenhydramine and/or tripelennamine.
  • drugs which can be delivered using the solidifying formulations of the present invention include, but are not limited to, tricyclic anti-depressants such as am ⁇ triptyline; anticonvulsants such as carbamazepine and alprazolam; N-methyl-D-aspartate (NMDA) antagonists such as ketamine; 5-HT2A receptor antagonists such as ketanserin; and immune modulators such as tacrolimus and picrolimus.
  • NMDA N-methyl-D-aspartate
  • Other drugs that can be delivered using the formulations and methods of the current invention include humectants, emollients, and other skin care compounds.
  • a pressurized container filled with a sprayable solidifying formulation for delivering a drug is prepared which includes a drug (e.g., ketoprofen, testosterone, etc.), a solidifying agents of polyvinyl alcohol (31 ,000-50,000 Mw) (Amresco) and esters of polyvinylmethylether/maleic anhydride copolymer (80,000-160,000 Mw) (Gantrez ES-425), a non-volatile solvent system of propylene glycol and glycerol, and a volatile solvent system of water and ethanol.
  • a drug e.g., ketoprofen, testosterone, etc.
  • a solidifying agents of polyvinyl alcohol 31 ,000-50,000 Mw)
  • esters of polyvinylmethylether/maleic anhydride copolymer 80,000-160,000 Mw
  • Gantrez ES-425 non-volatile solvent system of propylene glycol and glycerol
  • the propellant includes at least one of: propane, butane, isobutane, pentane, isopentane, fluro-chloro-hydrocarbons, diethyl ether, dimethyl ether, 1 ,1 difluoroethane, 1,1,1 ,2 tetrafluorethane, 1 ,1,1 ,2,3,3,3-heptafluoropropane, 1 ,1,1,3,3,3 hexafluoropropane, vinyl chloride, compressed carbon dioxide, compressed nitrogen, or a combination thereof.
  • the solidifying formulation quickly solidifies into a soft, coherent, and elastic solid layer after the evaporation of the propellant and the volatile solvent(s), and remains in intimate contact with the skin site until removal by the subject.
  • the solidified layer delivers a therapeutically effective amount of ketoprofen across the skin and into the ankle tissues over at least 2 hours, and preferably at least 8 hours, to control pain and inflammation.
  • the non-volatile solvent(s) also keeps the solidified layer soft, coherent, and elastic, as well as provides a flux-enabling solvent in the solidified layer to continuously deliver the ketoprofen through the skin in the absence of water or. more volatile solvents and propellants.
  • the solidified layer can be lifted from the skin due to its good cohesion.
  • the solidifying formulation quickly solidifies into a solid layer after the evaporation of the propellant.
  • the solid layer is soft, coherent, elastic, and remains in intimate contact with the skin site until it is removed.
  • the solidified layer delivers therapeutically effective amounts of testosterone across the skin and into the subject's systemic circulation over a period of at least 6 hours.
  • the non-volatile solvent serves as the vehicle for delivering testosterone and also keeps the solidified layer soft, coherent and elastic, as well as provides a flux-enabling solvent in the solidified layer to continuously deliver the testosterone through the skin in the absence of water or more volatile solvents and propellants.
  • the solidified layer can be removed from the skin due as a single large piece or as several large pieces due to its good cohesion.
  • a subject sprays solidifying formulation containing tetracaine from a pressurized container onto a skin site of a subject experiencing neuropathic pain.
  • the solidifying formulation includes tetracaine base, a solidifying agent of Plastoid B (neutral copolymer of butyl methacrylate and methyl methacrylate with a 120,000-180,000 Mw range), a non-volatile solvent system of mineral oil and isostearic acid, Gantrez ES-425 (esters of polyvinylmethylether/maleic anhydride copolymer a 80,000-160,000 Mw range for increased adhesion between the solidified layer and the skin), and propellants of dimethyl ether.
  • Plastoid B neutral copolymer of butyl methacrylate and methyl methacrylate with a 120,000-180,000 Mw range
  • Gantrez ES-425 esters of polyvinylmethylether/maleic anhydride copolymer a 80,000-160,000 Mw range for increased adh
  • the propellant evaporates quickly and the formulation solidifies into a soft, coherent, and flexible solid layer.
  • the solidified layer delivers tetracaine into the skin and controls the neuropathic pain for a sustained period of time.
  • the solidifying formulation includes ropivacaine base, a solidifying agent Plastoid B (neutral copolymer of butyl methacrylate and methyl methacrylate with a 120,000- 180,000 Mw range), a non-volatile solvent system including at least one of tetra hydroxy propyl ethylenediamine, triacetin, span 20, and isostearic acid.
  • the formulation also includes dimethyl ether as a propellant. After a layer of the formulation is sprayed on the skin, the propellant evaporates quickly and the formulation solidifies into a soft, coherent, and flexible solid layer.
  • Ropivacaine is delivered from the solidified layer into the skin over sustained period of time for treating the neuropathic pain.
  • a subject sprays solidifying formulation containing clobetasol propionate from a pressurized container onto a scalp area where the subject is suffering from alopecia.
  • the solidifying formulation includes clobetasol propionate, a solidifying agent offish gelatin, a non-volatile solvent system of propylene glycol and lsostearic acid, fumed silica as a filler (optional), and a fluorocarbon or dimethyl ether as a propellant.
  • the propellant evaporates quickly and the formulation solidifies into a soft, coherent, and flexible solid layer.
  • a therapeutically effective amount of clobetasol propionate is delivered from this layer into the scalp surface over at least 6 hours for promoting hair growth.
  • the formulation can be washed off in a shower or head wash, as the solidified layer is soluble in water.
  • a subject sprays a solidifying formulation containing clobetasol propionate from a pressurized container onto a palm skin area where the subject is suffering from hand dermatitis.
  • the formulation is similar to that in
  • Example 6 After a layer of the formulation is sprayed on the skin, the propellant evaporates quickly and the formulation solidifies into a soft, coherent, and flexible solid layer. Clobetasol propionate is delivered in from this solidified layer into the palm skin surface over at least 2 hours for suppressing the hand dermatitis.
  • the solidified layer is adhesive to the skin and also acts as a physical barrier to protect the skin from external substances that can cause or aggravate the dermatitis.
  • Example 8 A subject sprays a solidifying formulation containing an antibiotic agent from a pressurized container onto a skin area of bed sore or diabetes-induced ulcer.
  • the formulation includes an antibiotic, solidifying agent of polyvinyl alcohol, a non-volatile solvent system of glycerol, and a propellant of 1,1 ,1 ,2,3,3,3-heptafluoropropane (propellant).
  • the propellant evaporates quickly and the formulation solidifies into a soft, coherent, and flexible solid layer.
  • the antibiotic agent is delivered at therapeutically effective rates from this layer into the compromised skin surface over at least 2 hours for treating or preventing infection.
  • the solidified layer is adhesive to the skin surface and also acts as a physical barrier to protect the compromised skin area from external pathogens and touch by external objects that can cause pain.
  • a subject sprays solidifying formulation containing clobetasol propionate from an aerosol container onto a skin area where the subject is suffering from psoriasis.
  • the formulation includes the clobetasol propionate, a solidifying agent of polyvinyl alcohol, a non-volatile solvent system of glycerol, propylene glycol, and oleic acid, Gantrez ES-425 (esters of polyvinylmethylether/maleic anhydride copolymer with a 80,000-160,000 Mw range for increased adhesion between the solidified layer and the skin), and a hydrofluorocarbon as a propellant.
  • Clobetasol propionate is delivered from this layer into the psoriatic skin surface over at least 2 hours, and preferably over at least 6 hours, for suppressing the psoriasis.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)

Abstract

L'invention concerne des formulations pouvant être pulvérisées, des procédés d'administration de médicaments, et des couches résultantes solidifiées pour l'application cutanée d'un médicament. La formulation peut comprendre un médicament, un système de solvants non volatiles, un agent de solidification, et un agent propulseur. La formulation peut présenter une viscosité initiale de façon à pouvoir être expulsée d'un récipient à pompe sous pression ou manuelle, et appliquée à la surface de la peau en couches. Lors de l'application sur la peau, la formulation peut former une couche solidifiée après évaporation d'au moins une partie de l'agent propulseur.
EP06845634A 2005-12-14 2006-12-14 Formulations pouvant etre pulverisees et procedes pour administrer par voie cutanee des medicaments Withdrawn EP1959928A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75063705P 2005-12-14 2005-12-14
US79509106P 2006-04-25 2006-04-25
PCT/US2006/048060 WO2007070694A2 (fr) 2005-12-14 2006-12-14 Formulations pouvant etre pulverisees et procedes pour administrer par voie cutanee des medicaments

Publications (1)

Publication Number Publication Date
EP1959928A2 true EP1959928A2 (fr) 2008-08-27

Family

ID=38163552

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06845634A Withdrawn EP1959928A2 (fr) 2005-12-14 2006-12-14 Formulations pouvant etre pulverisees et procedes pour administrer par voie cutanee des medicaments

Country Status (5)

Country Link
EP (1) EP1959928A2 (fr)
JP (1) JP2009519957A (fr)
AU (1) AU2006326033A1 (fr)
CA (1) CA2633466A1 (fr)
WO (1) WO2007070694A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100076037A1 (en) * 2006-11-02 2010-03-25 Chiang Lillian W Methods of Treating Neuropathic Pain with Agonists of PPAR-gamma
CN107661293A (zh) * 2008-01-22 2018-02-06 得克萨斯大学体系董事会 用于局部麻醉和/或疼痛缓解的含有萃取溶剂的挥发性麻醉剂组合物
WO2010008600A1 (fr) * 2008-07-16 2010-01-21 Dermworx Incorporated Système d'apport de médicament topique
US20100160368A1 (en) 2008-08-18 2010-06-24 Gregory Jefferson J Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy
CA2752070C (fr) 2009-02-12 2017-11-28 Precision Dermatology, Inc. Compositions moussantes de peroxyde de benzoyle pour administration topique
EP2395839B1 (fr) 2009-02-13 2014-05-07 Topica Pharmaceuticals, Inc Formulation antifongique
EP2453747B1 (fr) 2009-07-13 2017-08-30 Medicis Pharmaceutical Corporation Formulations d'imiquimod à intensité de dosage plus faible et régimes posologiques courts pour traiter des verrues génitales et périanales
KR101619077B1 (ko) 2010-06-11 2016-05-10 레오 파마 에이/에스 비타민 ｄ 유사체 및 코르티코스테로이드를 포함하는 약제학적 분무 조성물
GB2496656B (en) * 2011-11-18 2015-12-09 Lrc Products Film-Forming Formulation
IN2014DN11232A (fr) * 2012-07-06 2015-10-02 Leo Pharma As
US20180271813A1 (en) * 2014-11-10 2018-09-27 Achelios Therapeutics, Inc. Sprayable analgesic compositions
CN105169464B (zh) * 2015-09-24 2018-05-15 中国人民解放军军事医学科学院放射与辐射医学研究所 一种天然蜂蜜伤口敷料及其制备方法与应用
CN111067919A (zh) * 2019-12-23 2020-04-28 李益谦 喷雾止痛剂

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030059471A1 (en) * 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
US20050058673A1 (en) * 2003-09-09 2005-03-17 3M Innovative Properties Company Antimicrobial compositions and methods

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2007070694A3 *

Also Published As

Publication number Publication date
JP2009519957A (ja) 2009-05-21
AU2006326033A1 (en) 2007-06-21
CA2633466A1 (fr) 2007-06-21
WO2007070694A3 (fr) 2008-12-24
WO2007070694A2 (fr) 2007-06-21

Similar Documents

Publication Publication Date Title
US20070189977A1 (en) Spray-on formulations and methods for dermal delivery of drugs
US20120294907A1 (en) Two or more solidifying agent-containing compositions and methods for dermal delivery of drugs
US20120301517A1 (en) Two or more non-volatile solvent-containing compositions and methods for dermal delivery of drugs
US20070196457A1 (en) Two or more volatile solvent-containing compositions and methods for dermal delivery of drugs
US20070196452A1 (en) Flux-enabling compositions and methods for dermal delivery of drugs
CA2633489C (fr) Compositions et procedes pour le traitement de conditions dermatologiques
AU2006326018B2 (en) Compositions and methods for dermally treating pain
US8741333B2 (en) Compositions and methods for treating dermatitis or psoriasis
EP1959928A2 (fr) Formulations pouvant etre pulverisees et procedes pour administrer par voie cutanee des medicaments
AU2006326034A1 (en) Flux-enabling compositions and methods for dermal delivery of drugs
US20070196323A1 (en) Polyvinyl alcohol-containing compositions and methods for dermal delivery of drugs
US20140314815A1 (en) Adhesive solid gel-forming formulations for dermal drug delivery
US20070189978A1 (en) Compositions and methods for dermally treating musculoskeletal pain
US20070196325A1 (en) Compositions and methods for dermally treating infections
US20080019927A1 (en) Compositions and methods for dermally treating neuropathy with minoxidil
CN101442987A (zh) 喷雾制剂和皮肤给药方法
CA2747845C (fr) Compositions et procedes pour le traitement dermique de la douleur
WO2007100376A2 (fr) compositions et procédés d'administration dermique de médicaments

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080625

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ZARS PHARMA, INC.

R17D Deferred search report published (corrected)

Effective date: 20081224

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100701